Elsinochrome A is a polyketide-derived pigment produced by the fungus Elsinoë fawcettii. It exhibits various biological activities, including antifungal, antibacterial, and antioxidant properties. Its synthesis involves a complex biosynthetic pathway, likely involving polyketide synthases and cytochrome P450 enzymes. Studies on elsinochrome A focus on its potential applications in medicine and agriculture, particularly as a natural fungicide and antibiotic. Its unique chemical structure and biological activities make it a valuable target for drug discovery and development.'
elsinochrome A: RN given refers to (trans)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 101523 |
MeSH ID | M0173607 |
Synonym |
---|
24568-67-0 |
elsinochrome a |
benzo(ghi)perylene-4,11-dione, 1,2-diacetyl-1,2-dihydro-5,10-dihydroxy-3,7,8,12-tetramethoxy-, trans- |
nsc 623609 |
benzo[ghi]perylene-4,11-dione, 1,2-diacetyl-1,2-dihydro-5,10-dihydroxy-3,7,8,12-tetramethoxy-, (1r,2r)-rel- |
AKOS040754693 |
Elsinochrome A (EA) is a perylene quinone natural photosensitizer. EA under light excitation generates reactive oxygen species (ROS) to induce apoptosis. EA can be used for treating tumors, that is so-called photodynamic therapy (PDT)
Excerpt | Reference | Relevance |
---|---|---|
"Elsinochrome A (EA) is a perylene quinone natural photosensitizer, photosensitizer under light excitation generates reactive oxygen species (ROS) to induce apoptosis, so can be used for treating tumors, that is so-called photodynamic therapy (PDT). " | ( Elsinochrome A induces cell apoptosis and autophagy in photodynamic therapy. Chen, S; Pan, L; Song, W; Yan, S; Yao, Y; Yu, S; Yuan, Y, 2023) | 3.8 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (5.88) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (41.18) | 29.6817 |
2010's | 7 (41.18) | 24.3611 |
2020's | 2 (11.76) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.49) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.88%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (94.12%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |